In a Parkinson's disease patient on levodopa, pramipexole, and rasagiline, can escitalopram be stopped?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Escitalopram Be Stopped in a Parkinson's Disease Patient on Levodopa, Pramipexole, and Rasagiline?

The decision to stop escitalopram in this patient depends critically on the indication for which it was prescribed, but from a safety perspective, the combination of escitalopram with rasagiline (an MAO-B inhibitor) requires caution due to serotonin syndrome risk, though this combination has been studied and appears generally safe when monitored appropriately.

Key Safety Considerations

Serotonin Syndrome Risk with MAO-B Inhibitors

The primary concern with this medication regimen is the combination of escitalopram (an SSRI) with rasagiline (an MAO-B inhibitor). While the FDA label for escitalopram 1 explicitly contraindicates use with MAOIs intended to treat psychiatric disorders, rasagiline is a selective MAO-B inhibitor used for Parkinson's disease, which presents a different risk profile than non-selective MAOIs.

Important evidence from clinical practice:

  • A large study examining combined rasagiline and antidepressant use in early Parkinson's disease found no serious adverse events suggestive of serotonin syndrome in patients taking this combination 2
  • The same study showed that rasagiline combined with antidepressants was associated with reduced worsening of depression, cognition, fatigue, and daytime sleepiness in Parkinson's patients 2

Drug Interaction Profile

The escitalopram FDA label 1 notes that escitalopram/citalopram has the least effect on CYP450 isoenzymes compared with other SSRIs, giving it a lower propensity for drug interactions—a favorable characteristic in this polypharmacy scenario.

Clinical Decision Algorithm

If Escitalopram Was Prescribed for Depression/Anxiety:

Do NOT abruptly stop escitalopram. The evidence suggests:

  1. Depression is common in Parkinson's disease and represents a significant non-motor symptom affecting quality of life
  2. The combination of rasagiline with antidepressants actually showed beneficial effects on depression and other non-motor symptoms in Parkinson's patients 2
  3. The safety profile appears acceptable when monitored appropriately

If continuing escitalopram:

  • Monitor closely for serotonin syndrome symptoms (agitation, confusion, tachycardia, hypertension, hyperthermia, hyperreflexia, diaphoresis) 1
  • Ensure patient/family can recognize early warning signs
  • The combination has been used safely in clinical trials 2

If Escitalopram Was Prescribed for REM Sleep Behavior Disorder (RBD):

Consider stopping escitalopram because:

  • SSRIs, including escitalopram's close relative paroxetine, have been associated with inducing or exacerbating RBD 3
  • A population study showed an increased risk ratio of being on antidepressants for patients with early-onset RBD 3
  • There is little evidence to support the use of SSRIs to treat RBD 3

Alternative RBD management in this patient:

  • The patient is already on pramipexole, which may have some benefit for RBD, though evidence is mixed 3
  • First-line RBD treatments are clonazepam or melatonin (3-12 mg at bedtime) 3

If Indication is Unclear or No Longer Valid:

Taper and discontinue escitalopram gradually because:

  • The FDA label 1 warns against abrupt discontinuation due to risk of discontinuation syndrome (dizziness, sensory disturbances, anxiety, irritability, insomnia)
  • Gradual dose reduction is recommended whenever possible 1
  • If intolerable symptoms occur during taper, resume the previous dose and decrease more slowly 1

Important Caveats

Discontinuation Syndrome

Escitalopram, while having a longer half-life than some SSRIs, can still cause discontinuation symptoms 4. Taper slowly over several weeks, monitoring for:

  • Dizziness, sensory disturbances (electric shock sensations)
  • Anxiety, irritability, agitation
  • Insomnia, headache
  • Mood changes

Monitoring During Continuation

If escitalopram is continued with rasagiline:

  • Watch for serotonin syndrome especially in the first 24-48 hours after any dose changes 4
  • Be aware that the patient is on multiple serotonergic agents (rasagiline has some serotonergic activity)
  • The risk appears low based on clinical trial data 2, but vigilance is warranted

Parkinson's Disease-Specific Considerations

  • Depression and anxiety are common non-motor symptoms in Parkinson's disease that significantly impact quality of life
  • The combination of rasagiline with antidepressants showed benefits beyond just motor symptoms 2
  • Stopping antidepressant therapy may worsen quality of life if depression/anxiety is inadequately treated

Bottom Line

Do not stop escitalopram solely because of the drug interaction concern with rasagiline—this combination has been used safely in clinical trials. However, if escitalopram was prescribed for RBD or if the original indication no longer applies, consider a gradual taper and discontinuation, potentially substituting appropriate RBD-specific therapy if needed. If prescribed for depression or anxiety, the combination appears beneficial and reasonably safe with appropriate monitoring.

References

3
Guideline

best practice guide for the treatment of rem sleep behavior disorder (rbd).

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010

4
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Related Questions

In a Parkinson’s disease patient receiving levodopa and pramipexole who is also taking rasagiline and escitalopram, can rasagiline be stopped abruptly?
What are the adverse effects of combining Mirapex (Pramipexole) and Sinemet (Carbidopa/Levodopa)?
Should a patient with Parkinson's disease take levodopa alone?
What antiemetic is an appropriate alternative to haloperidol for treating nausea in a patient with Parkinson's disease?
What are the initial medications for a 70-year-old newly diagnosed Parkinson's Disease (PD) patient?
In a child with congenital hyperinsulinism on diazoxide who recently contracted COVID‑19, how should severe reactive hypoglycemia be managed?
If a patient tolerates 7.5 mg weekly tirzepatide but does not achieve appetite suppression, what management steps should be taken?
What are the likely causes and recommended work‑up for a patient with hepatomegaly on ultrasound, elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and normal alkaline phosphatase, alpha‑fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 19‑9 (CA 19‑9), anti‑hepatitis C virus (anti‑HCV) antibodies, and hepatitis B surface antigen (HBsAg)?
In a patient on tirzepatide who does not achieve appetite suppression at 7.5 mg weekly but develops severe nausea and vomiting when the dose is increased to 10 mg, what is the recommended management?
What are the recommended contraceptive methods for a postpartum woman, including timing and breastfeeding considerations?
How can I convert an infusion rate expressed in micrograms per minute (µg/min) to milliliters per hour (mL/h)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question